Trials / Recruiting
RecruitingNCT07059403
A Study of SN2001 Dose, Safety & Immunogenicity in Healthy Adults
A Phase I, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability and Immunogenicity of SN2001 in Healthy Adult Subjects
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Chimivac INC · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a randomized, double-blind, placebo-controlled, multiple-ascending-dose study of SN2001 in healthy adult subjects. The study is designed to evaluate the safety, tolerability and immunogenicity of SN2001.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SN2001 | 100 µg, for subcutaneous (SC) injection |
| BIOLOGICAL | SN2001 | 200 µg, for subcutaneous (SC) injection |
| BIOLOGICAL | SN2001 | 300 µg, for subcutaneous (SC) injection |
Timeline
- Start date
- 2025-08-19
- Primary completion
- 2027-04-01
- Completion
- 2027-04-01
- First posted
- 2025-07-10
- Last updated
- 2025-08-24
Locations
1 site across 1 country: Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07059403. Inclusion in this directory is not an endorsement.